Santa Monica, CA, Sept. 11, 2018 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (OTCQB:BSGM, OTCQB:BSGMD) a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the $4.6 billion electrophysiology (EP) marketplace, today announced that the Company has issued their September 2018 letter to its shareholders providing them with updates on FDA 510(k) clearance, commercialization efforts, strategic relationships and enhancements to capital structure.
Recent Company Highlights
- Announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Company’s PURE EP™ System technology
- Raised $12.5 million in equity in 2018
- Announced upcoming uplist to Nasdaq stock exchange
- Appointed Mrs. Scott, the former Director of Strategic Partnerships at Biosense Webster, to accelerate engagement of physicians and assist with targeted commercialization efforts
- Announced collection of first-in-man data in the Q4 2018.
“The progress that BioSig has made so far in 2018 builds on our promise to deliver a world-class Company around our competencies and technology,” stated Mr. Kenneth Londoner, Founder, Chairman and CEO of BioSig Technologies. “With the success of securing financing and the strongest balance sheet we have had in our Company’s history, we are well equipped to move rapidly towards our goals. We see this as the beginning of a very rewarding cycle for all BioSig stakeholders and are committed to delivering shareholder value with the successful steps that we have taken, and we are excited about the future.”
To view BioSig Technologies’ Shareholder Letter please visit: LINK
About BioSig Technologies
BioSig Technologies is a medical device company developing a proprietary biomedical signal processing technology designed to improve the $4.6 billion electrophysiology (EP) marketplace (www.biosigtech.com). Led by a proven management team and a veteran, independent Board of Directors, Los Angeles-based BioSig Technologies is preparing to commercialize its PURE EP(TM) System. The technology has been developed to address an unmet need in a large and growing market.
The Company’s first product, PURE EP(TM) System, is a novel cardiac signal acquisition and display system which is engineered to assist electrophysiologists in clinical decision making during procedures to diagnose and treat patients with abnormal heart rates and rhythms. BioSig’s main goal is to deliver technology to improve upon catheter ablation treatments for the prevalent and potentially deadly arrhythmias: Atrial Fibrillation and Ventricular Tachycardia. BioSig has partnered with Minnetronix on technology development and received FDA 510(k) clearance for the PURE EP System in August 2018.
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our product candidates on a commercial scale on our own, or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key executives or scientists; and (v) difficulties in securing regulatory approval to market our product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
Contact: Natasha Drapeau BioSig Technologies, Inc. VP, Business Development & Corporate Finance 12600 Hill Country Blvd R-275 Austin, TX 78738 firstname.lastname@example.org 512-329-2643